JVS-vascular science最新文献

英文中文

Genome-First Approach to Rare and Common Variant Risk of Thoracic Aortic Aneurysm and Dissection 基因组优先研究胸主动脉瘤和夹层罕见和常见变异风险

Q3 Medicine

JVS-vascular science

Pub Date : 2024-01-01 Epub Date: 2024-10-25 DOI: 10.1016/j.jvssci.2024.100243

John Depaolo, Gina M. Biagetti, Renae Judy, Sarah Abramowitz, Nimesh Desai, Wilson Y. Szeto, Joseph E. Bavaria, Michael Levin, Dongchuan Guo, Dianna M. Milewicz, Scott M. Damrauer

引用次数: 0

Association of serum vitamin D with diagnosis and growth of abdominal aortic aneurysm 血清维生素 D 与腹主动脉瘤的诊断和生长的关系

Q3 Medicine

JVS-vascular science

Pub Date : 2024-01-01 Epub Date: 2024-06-19 DOI: 10.1016/j.jvssci.2024.100208

Shivshankar Thanigaimani PhD , Rachel E. Neale PhD , Mary Waterhouse PhD , Joseph V. Moxon PhD , Bu B. Yeap PhD , Paul E. Norman PhD , Leon Flicker PhD , Graeme J. Hankey PhD , Jason Jenkins PhD , Frank Quigley PhD , Michael W. Clarke PhD , Jonathan Golledge MA, FRCS, FRACS

Objective

We examined the associations between 25-hydroxy vitamin D (25(OH)D₃) concentration and the diagnosis and growth of abdominal aortic aneurysm (AAA).

Methods

AAA cases and healthy controls were recruited from vascular centers or the community. A subset of participants with AAA were monitored by repeat ultrasound examination to assess AAA growth. Serum 25(OH)D₃ concentration was measured using a validated mass spectrometry method and categorized into guideline-recommended cut-points after deseasonalization. The associations between deseasonalized 25(OH)D₃ concentration and AAA diagnosis and growth were examined using logistic regression and linear mixed effects modeling.

Results

A total of 4673 participants consisting of 873 (455 controls and 418 cases) from Queensland and 3800 (3588 controls and 212 cases) from Western Australia were recruited. For every 1 standard deviation increase in 25(OH)D₃ concentration, odds of AAA diagnosis was significantly reduced in both Queensland (adjusted odds ratio: 0.81; 95% confidence interval [CI]: 0.69-0.95; P = .009) and Western Australia (adjusted odds ratio: 0.80; 95% CI: 0.68-0.94; P = .005) cohorts. A subset of 310 eligible participants with small AAA from both regions were followed for a median of 4.2 (interquartile range: 2.0-5.8) years. Compared with vitamin D sufficient participants (50 to ˂75 nmol/L), annual mean AAA growth was significantly greater in those with higher vitamin D (≥75 nmol/L) (adjusted mean difference: 0.1 mm/y, 95% CI: 0.1-0.2; P < .001).

Conclusions

High 25(OH)D₃ concentration was paradoxically associated with a lower likelihood of AAA diagnosis and faster AAA growth. Further research is needed to resolve these conflicting findings.

目的我们研究了25-羟基维生素D（25(OH)D3）浓度与腹主动脉瘤（AAA）的诊断和生长之间的关系。方法从血管中心或社区招募AAA病例和健康对照组。一部分患有腹主动脉瘤的参与者通过重复超声波检查来评估腹主动脉瘤的生长情况。血清25(OH)D3浓度采用经过验证的质谱方法进行测量，并在去季节化后按指南推荐的切点进行分类。结果共招募了 4673 名参与者，其中昆士兰州 873 人（455 名对照者和 418 名病例），西澳大利亚州 3800 人（3588 名对照者和 212 名病例）。在昆士兰州和西澳大利亚州，25（OH）D3 浓度每增加 1 个标准差，确诊 AAA 的几率就会显著降低（调整后的几率比：0.81；95% 置信区间 [CI]：0.69-0.95；P<0.05）：调整后的几率比：0.81；95% 置信区间 [CI]：0.69-0.95；P = .009）和西澳大利亚队列（调整后的几率比：0.80；95% 置信区间：0.68-0.94；P = .005）。对来自这两个地区的 310 名符合条件的小型 AAA 患者进行了中位数为 4.2 年（四分位间距：2.0-5.8）的随访。结论高浓度的25（OH）D3与较低的AAA诊断可能性和较快的AAA生长速度之间存在矛盾。要解决这些相互矛盾的发现，还需要进一步的研究。

{"title":"Association of serum vitamin D with diagnosis and growth of abdominal aortic aneurysm","authors":"Shivshankar Thanigaimani PhD , Rachel E. Neale PhD , Mary Waterhouse PhD , Joseph V. Moxon PhD , Bu B. Yeap PhD , Paul E. Norman PhD , Leon Flicker PhD , Graeme J. Hankey PhD , Jason Jenkins PhD , Frank Quigley PhD , Michael W. Clarke PhD , Jonathan Golledge MA, FRCS, FRACS","doi":"10.1016/j.jvssci.2024.100208","DOIUrl":"10.1016/j.jvssci.2024.100208","url":null,"abstract":"<div><h3>Objective</h3><p>We examined the associations between 25-hydroxy vitamin D (25(OH)D<sub>3</sub>) concentration and the diagnosis and growth of abdominal aortic aneurysm (AAA).</p></div><div><h3>Methods</h3><p>AAA cases and healthy controls were recruited from vascular centers or the community. A subset of participants with AAA were monitored by repeat ultrasound examination to assess AAA growth. Serum 25(OH)D<sub>3</sub> concentration was measured using a validated mass spectrometry method and categorized into guideline-recommended cut-points after deseasonalization. The associations between deseasonalized 25(OH)D<sub>3</sub> concentration and AAA diagnosis and growth were examined using logistic regression and linear mixed effects modeling.</p></div><div><h3>Results</h3><p>A total of 4673 participants consisting of 873 (455 controls and 418 cases) from Queensland and 3800 (3588 controls and 212 cases) from Western Australia were recruited. For every 1 standard deviation increase in 25(OH)D<sub>3</sub> concentration, odds of AAA diagnosis was significantly reduced in both Queensland (adjusted odds ratio: 0.81; 95% confidence interval [CI]: 0.69-0.95; <em>P</em> = .009) and Western Australia (adjusted odds ratio: 0.80; 95% CI: 0.68-0.94; <em>P</em> = .005) cohorts. A subset of 310 eligible participants with small AAA from both regions were followed for a median of 4.2 (interquartile range: 2.0-5.8) years. Compared with vitamin D sufficient participants (50 to ˂75 nmol/L), annual mean AAA growth was significantly greater in those with higher vitamin D (≥75 nmol/L) (adjusted mean difference: 0.1 mm/y, 95% CI: 0.1-0.2; <em>P</em> < .001).</p></div><div><h3>Conclusions</h3><p>High 25(OH)D<sub>3</sub> concentration was paradoxically associated with a lower likelihood of AAA diagnosis and faster AAA growth. Further research is needed to resolve these conflicting findings.</p></div>","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"5 ","pages":"Article 100208"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666350324000191/pdfft?md5=53c6dec97c18728032cf8eccf8832233&pid=1-s2.0-S2666350324000191-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141953065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expression of the Aim2 Inflammasome in Skeletal is Modulated by Surgical Bypass And is a Target to Reduce Ischemic Myopathy in Pad 搭桥手术调节骨组织中Aim2炎性小体的表达，是减轻肌垫缺血性肌病的靶点

Q3 Medicine

JVS-vascular science

Pub Date : 2024-01-01 Epub Date: 2024-10-25 DOI: 10.1016/j.jvssci.2024.100228

Bowen Xie, Edwyn Assaf, Ricardo Ferrari, George Casale, Iraklis I. Pipinos, Ulka Sachdev

引用次数: 0

Lesion Site-Specific Mass Spectrometry Analysis of Human Carotid Plaques Reveals Strongest Association of the Necrotic Core And Fibrous Cap Proteome With Plaque Stability 人类颈动脉斑块病变部位特异性质谱分析揭示坏死核心和纤维帽蛋白质组与斑块稳定性的最强关联

Q3 Medicine

JVS-vascular science

Pub Date : 2024-01-01 Epub Date: 2024-10-25 DOI: 10.1016/j.jvssci.2024.100235

Nadja Sachs, Ankit Sinha, Elena Kratz, Jessica Pauli, Marie-Luise Engl, Hanna Winter, Hans-Henning Eckstein, Matthias Mann, Lars Maegdefessel

引用次数: 0

Myeloid Cell Lgr4 Contributes to Atherosclerotic Lesion Formation 髓样细胞Lgr4参与动脉粥样硬化病变的形成

Q3 Medicine

JVS-vascular science

Pub Date : 2024-01-01 Epub Date: 2024-10-25 DOI: 10.1016/j.jvssci.2024.100263

Ishita Kathuria, Ravi Varma Aithabathula, Naveed Pervaiz, Britney Le, Ki-Suk Kim, Jiqiu Wang, Udai P. Singh, Bhupesh Singla

引用次数: 0

Nr3c1-Sfrp1 Axis Regulates the Adipogenic Differentiation of Vcam1+ Fibro-adipogenic Progenitors in Chronic Limb-threatening Ischemia nr3c1 - strp1轴调控慢性肢体缺血中Vcam1+纤维脂肪祖细胞的成脂分化

Q3 Medicine

JVS-vascular science

Pub Date : 2024-01-01 Epub Date: 2024-10-25 DOI: 10.1016/j.jvssci.2024.100232

Qunsheng Dai, Changxin Wan, Yueyuan Xu, Brianna Garrett, Leo Akers, Derek Peters, James Otto, Christopher D. Kontos, Jason Ji, Yarui Diao, Kevin W. Southerland

引用次数: 0

A central arteriovenous fistula reduces systemic hypertension in a mouse model 中心动静脉瘘可降低小鼠模型的全身性高血压

Q3 Medicine

JVS-vascular science

Pub Date : 2024-01-01 Epub Date: 2024-02-15 DOI: 10.1016/j.jvssci.2024.100191

Anand Brahmandam MD , Rafael Alves BM , Hao Liu (刘灏) MD , Luis Gonzalez PhD , Yukihiko Aoyagi (青栁幸彦) MD , Yuichi Ohashi (大橋雄一) MD , John T. Langford MD , Carly Thaxton MD , Ryosuke Taniguchi (谷口良輔) MD, PhD , Weichang Zhang (张惟常) MD, PhD , Hualong Bai (白华龙) MD, PhD , Bogdan Yatsula PhD , Alan Dardik MD, PhD

Objective

A central arteriovenous fistula (AVF) has been proposed as a potential novel solution to treat patients with refractory hypertension. We hypothesized that venous remodeling after AVF creation in the hypertensive environment reduces systemic blood pressure but results in increased AVF wall thickness compared with remodeling in the normotensive environment.

Methods

A central AVF was performed in C57BL6/J mice previously made hypertensive with angiotensin II (Ang II); mice were sacrificed on postoperative day 7 or 21.

Results

In mice treated with Ang II alone, the mean systolic blood pressure increased from 90 ± 5 mmHg to 160 ± 5 mmHg at day 21; however, in mice treated with both Ang II and an AVF, the blood pressure decreased with creation of an AVF. There were significantly more PCNA-positive cells, SM22α/PCNA-positive cells, collagen I deposition, and increased Krüppel-like Factor 2 immunoreactivity in hypertensive mice with an AVF compared with normotensive mice with an AVF.

Conclusions

These data show that a central AVF decreases systemic hypertension as well as induces local alterations in venous remodeling.

目的中心动静脉瘘（AVF）被认为是治疗难治性高血压患者的一种潜在的新方法。我们假设，与正常血压环境下的重塑相比，在高血压环境下创建 AVF 后的静脉重塑可降低全身血压，但会导致 AVF 壁厚度增加。方法在先前用血管紧张素 II（Ang II）使之变为高血压的 C57BL6/J 小鼠中实施中心动静脉瘘；术后第 7 天或第 21 天处死小鼠。结果在单独使用血管紧张素 II 治疗的小鼠中，平均收缩压从 90 ± 5 mmHg 上升到第 21 天的 160 ± 5 mmHg；但在同时使用血管紧张素 II 和动静脉瘘治疗的小鼠中，血压随着动静脉瘘的建立而下降。与正常血压小鼠相比，有 AVF 的高血压小鼠 PCNA 阳性细胞、SM22α/PCNA 阳性细胞、胶原 I 沉积明显增多，Krüppel 样因子 2 免疫活性也有所提高。

{"title":"A central arteriovenous fistula reduces systemic hypertension in a mouse model","authors":"Anand Brahmandam MD , Rafael Alves BM , Hao Liu (刘灏) MD , Luis Gonzalez PhD , Yukihiko Aoyagi (青栁幸彦) MD , Yuichi Ohashi (大橋雄一) MD , John T. Langford MD , Carly Thaxton MD , Ryosuke Taniguchi (谷口良輔) MD, PhD , Weichang Zhang (张惟常) MD, PhD , Hualong Bai (白华龙) MD, PhD , Bogdan Yatsula PhD , Alan Dardik MD, PhD","doi":"10.1016/j.jvssci.2024.100191","DOIUrl":"10.1016/j.jvssci.2024.100191","url":null,"abstract":"<div><h3>Objective</h3><p>A central arteriovenous fistula (AVF) has been proposed as a potential novel solution to treat patients with refractory hypertension. We hypothesized that venous remodeling after AVF creation in the hypertensive environment reduces systemic blood pressure but results in increased AVF wall thickness compared with remodeling in the normotensive environment.</p></div><div><h3>Methods</h3><p>A central AVF was performed in C57BL6/J mice previously made hypertensive with angiotensin II (Ang II); mice were sacrificed on postoperative day 7 or 21.</p></div><div><h3>Results</h3><p>In mice treated with Ang II alone, the mean systolic blood pressure increased from 90 ± 5 mmHg to 160 ± 5 mmHg at day 21; however, in mice treated with both Ang II and an AVF, the blood pressure decreased with creation of an AVF. There were significantly more PCNA-positive cells, SM22α/PCNA-positive cells, collagen I deposition, and increased Krüppel-like Factor 2 immunoreactivity in hypertensive mice with an AVF compared with normotensive mice with an AVF.</p></div><div><h3>Conclusions</h3><p>These data show that a central AVF decreases systemic hypertension as well as induces local alterations in venous remodeling.</p></div>","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"5 ","pages":"Article 100191"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666350324000026/pdfft?md5=60786e70b011585e96e3a0ee22d68666&pid=1-s2.0-S2666350324000026-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139832835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cd40 is Required For B1b Cell Homeostasis in Atherosclerosis 动脉粥样硬化中B1b细胞稳态需要Cd40

Q3 Medicine

JVS-vascular science

Pub Date : 2024-01-01 Epub Date: 2024-10-25 DOI: 10.1016/j.jvssci.2024.100241

Katrin Nitz, Myrthe Reiche, Oom Pattarabajinard, Aditi Upadhye, Claudia van Tiel, Angela M. Taylor, Stephen G. Malin, Christoph J. Binder, Norbert Gerdes, Cornelia M. Weyand, Christian Weber, Dorothee Atzler, Coleen A. McNamara, Esther Lutgens

引用次数: 0

The Tgfb-Whsc1 Axis Drives Macrophage to Myofibroblast Transition During Wound Repair Tgfb-Whsc1轴在伤口修复过程中驱动巨噬细胞向肌成纤维细胞转变

Q3 Medicine

JVS-vascular science

Pub Date : 2024-01-01 Epub Date: 2024-10-25 DOI: 10.1016/j.jvssci.2024.100230

Kevin Dale Mangum, Tyler Bauer, Amrita Joshi, William Melvin, Emily Barrett, Sonya Wolf, Jadie Moon, James Shadiow, Andrea T. Obi, Johann Gudjonsson, Frank Davis, Katherine A. Gallagher

引用次数: 0

Dyslipidemia impairs collateral artery formation after hindlimb ischemia: Adding insult to injury 血脂异常会影响后肢缺血后的侧支动脉形成：雪上加霜

Q3 Medicine

JVS-vascular science

Pub Date : 2024-01-01 Epub Date: 2024-04-05 DOI: 10.1016/j.jvssci.2024.100204

Ali H. Hakim MD , Luke Brewster MD PhD

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

JVS-vascular science

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀